Early Use of Inhaled Nitric Oxide in Preterm Infants: Is there a Rationale for Selective Approach?

Abstract

Background Inhaled nitric oxide (iNO) is being increasingly used in preterm infants < 34 weeks with hypoxemic respiratory failure (HRF) and/or pulmonary hypertension (PH).

Objective To evaluate the risk factors, survival characteristics, and lung histopathology in preterm infants with PH/HRF.

Methods Retrospective chart review was conducted to determine characteristics of 93 preterm infants treated with iNO in the first 28 days and compared with 930 matched controls. Factors associated with survival with preterm HRF and smooth muscle actin from nine autopsies were evaluated.

Results Preterm neonates treated with iNO had a higher incidence of preterm prolonged rupture of membrane (pPROM ≥ 18 hours), oligohydramnios and delivered by C-section. In infants treated with iNO, antenatal steroids (odds ratio [OR],3.7; confidence interval [CI], 1.2–11.3; p = 0.02), pPROM (OR, 1.001; CI, 1.0–1.004; p = 0.3), and oxygenation response to iNO (OR, 3.7; CI, 1.08–13.1; p = 0.037) were associated with survival. Thirteen infants with all three characteristics had 100% (13/13) survival without severe intraventricular hemorrhage (IVH)/periventricular leukomalacia (PVL) compared with 48% survival (12/25, p = 0.004) and 16% severe IVH/PVL without any of these factors. Severity of HRF correlated with increased smooth muscle in pulmonary vasculature.

Conclusion Preterm infants with HRF exposed to antenatal steroids and pPROM had improved oxygenation with iNO and survival without severe IVH/PVL. Precisely targeting this subset may be beneficial in future trials of iNO.

Keywords

inhaled nitric oxide - hypoxemic respiratory failure - preterm prolonged rupture of membrane - pulmonary hypertension - smooth muscle area ratio

• References

• 1 Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006; (4) CD000399
• 2 Askie LM, Ballard RA, Cutter GR , et al; Meta-analysis of Preterm Patients on Inhaled Nitric Oxide Collaboration. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics 2011; 128 (4) 729-739
• 3 Cole FS, Alleyne C, Barks JD , et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 2011; 127 (2) 363-369
• 4 Kumar P ; Committee on Fetus and Newborn; American Academy of Pediatrics. Use of inhaled nitric oxide in preterm infants. Pediatrics 2014; 133 (1) 164-170
• 5 Ellsworth MA, Harris MN, Carey WA, Spitzer AR, Clark RH. Off-label use of inhaled nitric oxide after release of NIH consensus statement. Pediatrics 2015; 135 (4) 643-648
• 6 Finer NN, Evans N. Inhaled nitric oxide for the preterm infant: evidence versus practice. Pediatrics 2015; 135 (4) 754-756
• 7 Field D, Elbourne D, Truesdale A , et al; INNOVO Trial Collaborating Group. Neonatal Ventilation With Inhaled Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure: the INNOVO multicentre randomised controlled trial (ISRCTN 17821339). Pediatrics 2005; 115 (4) 926-936
• 8 Kinsella JP, Walsh WF, Bose CL , et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet 1999; 354 (9184): 1061-1065
• 9 Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 77 (3) F185-F190
• 10 Van Meurs KP, Wright LL, Ehrenkranz RA , et al; Preemie Inhaled Nitric Oxide Study. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005; 353 (1) 13-22
• 11 Chock VY, Van Meurs KP, Hintz SR , et al; NICHD Neonatal Research Network. Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia. Am J Perinatol 2009; 26 (4) 317-322
• 12 Geary C, Whitsett J. Inhaled nitric oxide for oligohydramnios-induced pulmonary hypoplasia: a report of two cases and review of the literature. J Perinatol 2002; 22 (1) 82-85
• 13 Keszler M. Guidelies for rationnal and cost-effective use of iNO therapy in term and preterm infants. J Clin Neonatol 2012; 1 (2) 59-63
• 14 Peliowski A, Finer NN, Etches PC, Tierney AJ, Ryan CA. Inhaled nitric oxide for premature infants after prolonged rupture of the membranes. J Pediatr 1995; 126 (3) 450-453
• 15 Aikio O, Metsola J, Vuolteenaho R, Perhomaa M, Hallman M. Transient defect in nitric oxide generation after rupture of fetal membranes and responsiveness to inhaled nitric oxide in very preterm infants with hypoxic respiratory failure. J Pediatr 2012; 161 (3) 397-403.e1
• 16 Dani C. Does it exist pulmonary hypertension in the ELBW infants?. Italian J Pediatrics 2015; 41 (Suppl. 01) A6
• 17 Cheng DR, Peart S, Tan K, Sehgal A. Nitric therapy in preterm infants: rationalised approach based on functional neonatal echocardiography. Acta Paediatr 2016; 105 (2) 165-171
• 18 Rabinovitch M. Pulmonary hypertension: pathophysiology as a basis for clinical decision making. J Heart Lung Transplant 1999; 18 (11) 1041-1053
• 19 Baker CD, Abman SH, Mourani PM. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Pediatr Allergy Immunol Pulmonol 2014; 27 (1) 8-16
• 20 Murphy JD, Vawter GF, Reid LM. Pulmonary vascular disease in fatal meconium aspiration. J Pediatr 1984; 104 (5) 758-762
• 21 Lakshminrusimha S, Keszler M. Persistent pulmonary hypertension of the newborn. Neoreviews 2015; 16 (12) e680-e692
• 22 Iyer NP, Mhanna MJ. Non-invasively derived respiratory severity score and oxygenation index in ventilated newborn infants. Pediatr Pulmonol 2013; 48 (4) 364-369
• 23 Ballard RA, Truog WE, Cnaan A , et al; NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355 (4) 343-353
• 24 Thibeault DW, Truog WE, Ekekezie II. Acinar arterial changes with chronic lung disease of prematurity in the surfactant era. Pediatr Pulmonol 2003; 36 (6) 482-489
• 25 Thibeault DW, Kilbride HK. Increased acinar arterial wall muscle in preterm infants with PROM and pulmonary hypoplasia. Am J Perinatol 1997; 14 (8) 457-460
• 26 Mourani PM, Abman SH. Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond. Curr Opin Pediatr 2013; 25 (3) 329-337
• 27 Walther FJ, Benders MJ, Leighton JO. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 1992; 90 (6) 899-904
• 28 Kumar VH, Hutchison AA, Lakshminrusimha S, Morin III FC, Wynn RJ, Ryan RM. Characteristics of pulmonary hypertension in preterm neonates. J Perinatol 2007; 27 (4) 214-219
• 29 Mirza H, Ziegler J, Ford S, Padbury J, Tucker R, Laptook A. Pulmonary hypertension in preterm infants: prevalence and association with bronchopulmonary dysplasia. J Pediatr 2014; 165 (5) 909-14.e1
• 30 Mirza H, Ziegler J, Ford S, Padbury J, Tucker R, Laptook A. Temporal profile of early pulmonary hypertension in preterm infants. Am J Perinatol 2016; 33 (9) 903-909
• 31 Desandes R, Desandes E, Droullé P, Didier F, Longrois D, Hascoët JM. Inhaled nitric oxide improves oxygenation in very premature infants with low pulmonary blood flow. Acta Paediatr 2004; 93 (1) 66-69
• 32 Dani C, Bertini G, Pezzati M, Filippi L, Cecchi A, Rubaltelli FF. Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome. Acta Paediatr 2006; 95 (9) 1116-1123
• 33 Evans N. Towards rational use of inhaled Nitric Oxide in preterm babies. Acta Paediatr 2016; 105 (2) 121-122
• 34 Arul N, Konduri GG. Inhaled nitric oxide for preterm neonates. Clin Perinatol 2009; 36 (1) 43-61
• 35 Stutchfield P, Whitaker R, Russell I ; Antenatal Steroids for Term Elective Caesarean Section (ASTECS) Research Team. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ 2005; 331 (7518): 662
• 36 Crossley KJ, Morley CJ, Allison BJ , et al. Blood gases and pulmonary blood flow during resuscitation of very preterm lambs treated with antenatal betamethasone and/or curosurf: effect of positive end-expiratory pressure. Pediatr Res 2007; 62 (1) 37-42
• 37 Crossley KJ, Morley CJ, Allison BJ , et al. Antenatal corticosteroids increase fetal, but not postnatal, pulmonary blood flow in sheep. Pediatr Res 2009; 66 (3) 283-288
• 38 Konduri GG, Bakhutashvili I, Eis A, Afolayan A. Antenatal betamethasone improves postnatal transition in late preterm lambs with persistent pulmonary hypertension of the newborn. Pediatr Res 2013; 73 (5) 621-629
• 39 Gao Y, Tolsa JF, Shen H, Raj JU. A single dose of antenatal betamethasone enhances isoprenaline and prostaglandin E2-induced relaxation of preterm ovine pulmonary arteries. Biol Neonate 1998; 73 (3) 182-189
• 40 Gao Y, Zhou H, Tolsa JF, Shen H, Raj JU. Antenatal betamethasone therapy augments isoproterenol and prostaglandin E2-mediated relaxation of preterm ovine pulmonary veins. Pediatr Res 1997; 42 (4) 545-549
• 41 Zhou H, Gao Y, Raj JU. Antenatal betamethasone therapy augments nitric oxide-mediated relaxation of preterm ovine pulmonary veins. J Appl Physiol (1985) 1996; 80 (2) 390-396
• 42 Gao Y, Zhou H, Raj JU. Antenatal betamethasone therapy potentiates nitric oxide-mediated relaxation of preterm ovine coronary arteries. Am J Physiol 1996; 270 (2 Pt 2): H538-H544
• 43 Abman SH, Hansmann G, Archer SL , et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation 2015; 132 (21) 2037-2099
• 44 Konduri GG, Menzin J, Frean M, Lee T, Potenziano J, Singer J. Inhaled nitric oxide in term/late preterm neonates with hypoxic respiratory failure: estimating the financial impact of earlier use. J Med Econ 2015; 18 (8) 612-618
• 45 Sharma V, Berkelhamer SK, Lakshminrusimha S. Persistent pulmonary hypertension of the newborn. Maternal Health, Neonatology and Perinatology. BMC 2015; 1 (14) 1-18
• 46 Farrow KN, Lakshminrusimha S, Reda WJ , et al. Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295 (6) L979-L987
• 47 Sheehy AM, Burson MA, Black SM. Nitric oxide exposure inhibits endothelial NOS activity but not gene expression: a role for superoxide. Am J Physiol 1998; 274 (5 Pt 1): L833-L841
• 48 Black SM, Heidersbach RS, McMullan DM, Bekker JM, Johengen MJ, Fineman JR. Inhaled nitric oxide inhibits NOS activity in lambs: potential mechanism for rebound pulmonary hypertension. Am J Physiol 1999; 277 (5 Pt 2): H1849-H1856
• 49 Ohara T, Ogata H, Tezuka F. Histological study of pulmonary vasculature in fatal cases of persistent pulmonary hypertension of the newborn. Tohoku J Exp Med 1991; 164 (1) 59-66
• 50 Austin ED, Loyd JE. Toward precision medicine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192 (11) 1272-1274
• 51 Kinsella JP, Steinhorn RH, Krishnan US , et al. Recommendations for the use of inhaled nitric oxide therapy in premature newborns with severe pulmonary hypertension. J Pediatr 2016; 170: 312-314